How To Earn $500 A Month From Pfizer Stock
Pfizer Inc. (NYSE: PFE) shares closed almost flat on Friday, but lost around 44% during 2023.
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Pfizer’s 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE: PFE),
Looking Into Seagen’s Recent Short Interest
Seagen’s (NYSE:SGEN) short percent of float has fallen 5.96% since its last report. The company recently reported that…
Pfizer’s Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE: SHAK)
Why Is US Pharma Giant Pfizer Stock Trading Lower Today?
Pfizer Inc (NYSE: PFE) provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen Inc (NASDAQ: SGEN) transaction.
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
Pfizer Inc (NYSE: PFE)
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)
What the Options Market Tells Us About Seagen
Financial giants have made a conspicuous bearish move on Seagen. Our analysis of options history for Seagen (NASDAQ:SGEN)…
TUKYSA In Combination With Antibody-Drug Conjugate Ado-Trastuzumab Emtansine Improves Progression-Free Survival In Patients With Previously Treated HER2-Positive Metastatic Breast Cancer
-- Results of Phase 3 HER2CLIMB-02 trial featured in an oral presentation and official press program at the 2023 San Antonio Breast Cancer Symposium --Seagen Inc. (NASDAQ:SGEN) today announced data from the Phase 3